Table 1

Basic and clinical characteristics at baseline of the 22 patients

Age (years), mean (range)43.3 (21–61)
Disease duration psoriasis (years), median (range)12.7 (1–53)
Disease duration PsA (years), median (range)6.3 (1–18)
Clinical phenotype: PA/OA/DIP915/6/1
Concomitant MTX use, n (%)12 (55)
MTX dose (mg/week), median (range)17.5 (10–25)
DAS28, mean (SEM)4.92 (0.25)
PASI, median (IQR)5.7 (1.5–7.0)
ESR (mm/h), median (IQR)17.5 (7.8–31)
CRP (mg/l), median (IQR)6.2 (2.6–25.7)
  • CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; DIP, distal interphalangeal joint; ESR, erythrocyte sedimentation rate; IQR, interquartile range; MTX, methotrexate; OA, oligoarticular; PA, polyarticular; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.